Robert Ajer News Today

Robert W. Baird downgraded shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) from an outperform rating to a neutral rating in a research note released on Friday morning, Marketbeat reports. The brokerage currently has $72.00 target price on the biotechnology company’s stock, down from their previous target price of $104.00. Several other brokerages have also […]

Evercore ISI began coverage on shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) in a research report report published on Tuesday, Marketbeat reports. The firm issued an outperform rating and a $113.00 price target on the biotechnology company’s stock. Several other equities research analysts have also recently issued reports on BMRN. Wells Fargo & Company […]

Motley Fool Wealth Management LLC reduced its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 3.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 470,289 shares of the biotechnology company’s stock after selling 18,667 shares during the quarter. […]

BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its price objective decreased by Morgan Stanley from $115.00 to $112.00 in a research note released on Friday, Benzinga reports. Morgan Stanley currently has an overweight rating on the biotechnology company’s stock. Several other equities research analysts have also recently weighed in on the company. Cantor Fitzgerald reaffirmed […]

BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its target price lowered by Citigroup from $94.00 to $91.00 in a research note published on Thursday morning, Benzinga reports. Citigroup currently has a neutral rating on the biotechnology company’s stock. Several other research analysts have also issued reports on BMRN. Royal Bank of Canada restated a sector […]

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report)‘s stock had its “overweight” rating reiterated by analysts at Cantor Fitzgerald in a report issued on Thursday, Benzinga reports. They currently have a $110.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s price target would indicate a potential upside of 34.47% from the stock’s previous close. Several […]

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) updated its FY24 earnings guidance on Wednesday. The company provided earnings per share guidance of $2.75-2.95 for the period, compared to the consensus earnings per share estimate of $2.59. The company issued revenue guidance of $2.7-2.8 billion, compared to the consensus revenue estimate of $2.75 billion. BioMarin Pharmaceutical […]

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) updated its FY 2024 earnings guidance on Wednesday. The company provided earnings per share guidance of 2.750-2.950 for the period, compared to the consensus earnings per share estimate of 1.650. The company issued revenue guidance of $2.7 billion-$2.8 billion, compared to the consensus revenue estimate of $2.8 billion. […]

Fort Washington Investment Advisors Inc. OH lowered its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 10.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,165,589 shares of the biotechnology company’s stock after selling 142,656 shares […]

Andra AP fonden lowered its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 18.8% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 72,200 shares of the biotechnology company’s stock after selling 16,700 shares during the quarter. Andra AP fonden’s holdings […]